Live from the registry
Clinical trials
Live from the ClinicalTrials.gov registry. Registration is not endorsement: a registered trial may be small, early, or studying a single age-associated condition rather than ageing itself. Always read the registry entry before drawing conclusions.
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
active not recruitingCanadian Cancer Trials Group · PHASE2 · 137 participants
Primary outcome measured: Objective Response
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
availableCelcuity Inc
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
completedDermatology Specialties Limited Partnership · PHASE2, PHASE3 · 107 participants
Primary outcome measured: Percentage of Participants Obtaining Successful Treatment
Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
withdrawnUniversity of Minnesota · NA
Primary outcome measured: 1. Change in maximal intimal thickness
Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
completedUniversity at Buffalo · PHASE4 · 58 participants
Primary outcome measured: Number of Participants With Graft Survival at 12 Months
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
terminatedSanten Inc. · PHASE2 · 62 participants
Primary outcome measured: Best-corrected visual acuity by ETDRS
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
completedColumbia University · PHASE1 · 9 participants
Primary outcome measured: Maximum Tolerated Dose (MTD) of Cisplatin
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
terminatedDana-Farber Cancer Institute · PHASE2 · 15 participants
Primary outcome measured: To Determine the Rate of Grade II-IV Acute GVHD When Sirolimus and Mycophenolate Mofetil or Sirolimus, Mycophenolate Mofetil and Bortezomib is Used for GVHD Prophylaxis After Allogeneic Stem Cell Transplantation in Patients With Hematologic Malignancies
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
recruitingAmerican Society of Clinical Oncology · PHASE2 · 4,200 participants
Primary outcome measured: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Study Evaluating Sirolimus in Kidney Transplant Recipients.
completedWyeth is now a wholly owned subsidiary of Pfizer · PHASE3 · 150 participants
Primary outcome measured: To evaluate the safety and efficacy of an immunosuppressive regimen using synergic action of SRL and CsA, but which will limit (ab initio), the nephrotic effect of such combination. To compare Rapamune/low dose Cyclosporine vs. Rapamune/Steroids.
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
completedM.D. Anderson Cancer Center · PHASE1 · 37 participants
Primary outcome measured: Maximum tolerated dose and/or recommended phase II dose
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
completedNational Cancer Institute (NCI) · PHASE1 · 27 participants
Primary outcome measured: Incidence of dose-limiting toxicities (DLTs) for the combination of cixutumumab and everolimus with octreotide acetate
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
completedChildren's Hospital of Fudan University · PHASE4 · 92 participants
Primary outcome measured: response to treatment
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
completedNational Cancer Institute (NCI) · PHASE2 · 208 participants
Primary outcome measured: Number of Participants With an Objective Response
Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease
terminatedWashington University School of Medicine · PHASE1 · 1 participants
Primary outcome measured: Safety and tolerability of treatment regimen as measured by grade 3, 4, and 5 toxicities
Study of Everolimus (RAD001) in Combination With Lenalidomide
completedEmory University · PHASE1 · 44 participants
Primary outcome measured: Number of Participants With Dose Limiting Toxicities (DLT) at Each Dose Level
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
recruitingUniversity Hospital, Strasbourg, France · PHASE4 · 212 participants
Primary outcome measured: The primary endpoint is the rate of patients showing a change in the SOFA (Sequential Organ Failure Assessment) score of at least 4 points
Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation
unknownPeking Union Medical College Hospital · PHASE4 · 20 participants
Primary outcome measured: Total venous malformation lesion load
Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial
completedMayo Clinic · PHASE1 · 13 participants
Primary outcome measured: Frailty
Study of Rapamycin Plus Ketoconazole in Advanced Cancers
completedUniversity of Chicago · PHASE1 · 57 participants
Primary outcome measured: maximum tolerated dose
Source: ClinicalTrials.gov API v2, retrieved live and cached for one hour. Longevity Record is not affiliated with ClinicalTrials.gov or the US National Library of Medicine. Trial participation is a medical decision — see our disclaimer.